NCT07161687Active, not recruiting
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
HYMPAVZI S.C. INJECTION 150 MG PEN SPECIAL INVESTIGATION
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 2 Sept 2025
- Start date
- 30 Oct 2025
- Primary completion date
- 11 Apr 2030
- Lead sponsor
- Pfizer
- Diseases
- Haemophilia
- NCT number
- NCT07161687
What you commit to
- Study type: Observational
- Planned participants: 50
- From 30 Oct 2025 to the primary completion date, 11 Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- Patients who have received at least one dose of this drug after the launch of this drug
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.